Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

7.8K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Metastasis02:30

Metastasis

6.8K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The evolution of prostate cancer grading: from Gleason score to risk taxonomy and the artificial intelligence revolution.

Virchows Archiv : an international journal of pathology·2026
Same author

Divergent effects of PLA2G7 on prostate cancer biochemical recurrence in European American and African American men.

Journal of the National Cancer Institute·2026
Same author

Clinical and Molecular Characterization of Clear Cell Adenocarcinoma of the Urinary Tract: A Multi-Institutional Study.

The American journal of surgical pathology·2026
Same author

p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors.

Cancer cell·2026
Same author

Comparison of glass-based and whole-slide image-based grade assignment for clear-cell and papillary renal cell carcinoma: a multi-cohort, international reproducibility study.

Histopathology·2025
Same author

Characterization of CD8+ and FOXP3+ T-Cell Ratios in Tumor and Stromal Compartments of Penile Squamous Cell Carcinoma: An Analysis Across Histologic Subtypes and Grades.

International journal of surgical pathology·2025

Related Experiment Video

Updated: Mar 29, 2026

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.3K

Molecular Updates in Prostate Cancer.

George J Netto1

  • 1Johns Hopkins University, Baltimore, Maryland, USA.

Surgical Pathology Clinics
|November 28, 2015
PubMed
Summary

New molecular markers and genomic signatures show promise for improving prostate cancer (PCA) screening, early detection, and prognosis. These advancements offer potential clinical benefits for understanding PCA development and progression.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Current prostate cancer (PCA) screening and prognostic methods can be enhanced by novel molecular and genomic markers.
  • Understanding the genetic and epigenetic landscape of PCA is crucial for improving patient outcomes.

Purpose of the Study:

  • To review molecular markers and genomic signatures for PCA.
  • To highlight the clinical implications of recent genome-wide assessments in PCA.
  • To discuss advancements in early detection and prognostic parameters for PCA.

Main Methods:

  • Literature review of molecular markers and genomic signatures relevant to PCA.
  • Discussion of genetic susceptibility, epigenetic alterations (e.g., ETS gene fusions, PTEN alterations), and urine-based markers (e.g., PCA3).
Keywords:
CarcinogenesisGenomic classificationPCA3Prostate cancer

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.3K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

17.3K

Related Experiment Videos

Last Updated: Mar 29, 2026

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.3K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.3K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

17.3K
  • Analysis of genome-wide assessment data impacting PCA understanding.

    • Main Results:

    • A range of molecular markers and genomic signatures are identified as potential adjuncts to current PCA strategies.
    • Specific markers like ETS gene fusions, PTEN alterations, and PCA3 show relevance.
    • Genome-wide studies have advanced the understanding of PCA development and progression pathways.

    Conclusions:

    • Molecular markers and genomic signatures are poised to augment existing PCA screening, detection, and prognostic tools.
    • These markers offer significant potential for clinical application in managing prostate cancer.
    • Continued research into genomic alterations will further refine our approach to PCA.